Anlotinib Anticancer Drugs Oncology Pharmacology Physiotherapy

Anlotinib (Description-2)

In this article we will discuss Anlotinib (Description-2)

In this article we will discuss Anlotinib (Description-2). So, let’s get started.

The China Food and Drug Administration (CFDA) approved single agent anlotinib as a third-line treatment for patients with advanced NSCLC. Moreover, a randomized phase IIB trial demonstrated that anlotinib significantly prolonged the median PFS in patients with advanced soft tissue sarcoma (STS). Anlotinib also showed promising efficacy in patients with advanced medullary thyroid carcinoma and metastatic renal cell carcinoma (mRCC). The tolerability profile of anlotinib is similar to that of other tyrosine kinase inhibitors that target VEGFR and other tyrosine kinase-mediated pathways; however, anlotinib has a significantly lower incidence of grade 3 or higher side effects compared to that of sunitinib.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.